Ishikawa D, et al: Applications of fecal microbiota transplantation Reviews Juntendo Medical Journal 2025. 71(2), 68-75 Current Applications and Future Prospects of Fecal Microbiota Transplantation Dai ISHIKAWA1, 2),Xiaochen ZHANG1),Akihito NAGAHARA2) 1)Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan TEL: +81-03-3813-3111 E-mail: dai@juntendo.ac.jp 360th Triannual Meeting of the Juntendo Medical Society “New developments in transplant medicine from Juntendo universdity”〔Held on Sep. 14, 2023〕 〔Received Nov. 25, 2024〕 〔Accepted Dec. 11, 2024〕 J-STAGE Advance published date: Mar. 12, 2025 Copyright © 2025 The Juntendo Medical Society. This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited. doi: 10.14789/ejmj.JMJ24-0045-R 68 Juntendo Medical Journal 71(2), 2025 Established application of FMT in CDI Exploratory applications of FMT in IBD Improper antibiotic use can cause dysbiosis, which increases the risk of CDI8). CDI has also gradually shifted from being predominantly a nosocomial condition, with >41% of cases currently being community acquired9). In Japan, vancomycin (VCM) and metronidazole (MNZ) are the primary treatments; however, refractory cases are encountered in clinical practice10). Patients with prolonged antibiotic use, long-term hospitalization, advanced age (>65 years), or other diseases are particularly prone to recurrent or refractory CDI8). The earliest literature on FMT for refractory CDI dates back to 1958. Eiseman et al.11) reported four patients with recurrent pseudomembranous colitis. FMT was performed by administering one to three enemas. None of the patients showed improvements in symptoms or reported side effects. Although some individual case reports have been published since then, no systematic studies have been conducted. In 2013, van Nood et al.3) conducted a randomized controlled trial (RCT) comparing FMT with standard treatment (VCM). The trial reported an 81% cure rate after a single FMT (13 out of 16 patients) and a 67% cure rate (2 out of 3) in previously unresponsive patients after another FMT from a different donor, culminating in an impressive total cure rate of 94%. Furthermore, the analysis of intestinal microbiota revealed improved diversity after FMT, closely resembling that of healthy donors. Based on the these findings, the European and American CDI treatment guidelines4, 12) recommended for patients with recurrent CDI who are unresponsive to VCM. In Europe and the United States, the emergence of nosocomial infection caused by an antimicrobial-resistant North American Pulsedfield gel electrophoresis type 1 (NAP1) strain has exacerbated the issue of nosocomial infections, with NAP1 detected in 30% of patients with hospitalacquired infections13). The rising prevalence of drug-resistant and refractory CDI and the worsening of the disease have made the FMT an increasingly important drug-independent intestinal microbiome therapy. Although Japan has not encountered severe CDI issues, globalization necessitates the strengthening of the country’s FMT implementation systems to address potential future challenges effectively. In Japan, the number of patients with UC has been steadily increasing14). Although the emergence of biologics and immunosuppressants has improved remission rates, patients are compelled to use these medications in the long-term owing to the absence of standardized discontinuation criteria. The use of these drugs is challenging for pediatric and older patients due to immune tolerance issues and the significant risk of developing side effects15, 16). Therefore, a fundamental treatment method with fewer side effects is needed. As UC is a representative disease associated with dysbiosis, FMT has emerged as a promising treatment option for UC2). The earliest study investigating the use of FMT for UC was conducted by Bennet et al. in 198917), who administered a single FMT enema following antibiotic treatment, which resulted in patient remission. Subsequent studies have the reported the effectiveness of FMT in UC treatment; however, most of these studies are case reports, and the therapeutic effects remain a topic for discussion. To date, six double-blind RCTs on FMT for UC have been reported (Table 1). In May 2015, two RCTs18, 19) on FMT for UC were published by the American journal Gastroenterology. In a study by Moayyedi et al., the FMT group with UC received 50 mL of healthy donor stool via enema once a week for six consecutive weeks, while the placebo group received water. The results revealed that the remission rate in the FMT group (24%) was significantly higher than that in the placebo group (5%). In the study by Rossen et al., patients with UC were allocated into two groups: the FMT group, which received donor stool via a nasoduodenal tube, and the control group, which received autologous stool. Both groups underwent a total of two treatments at weeks 0 and 3. The results indicated that the remission rate in the FMT group (30.4%) was not significantly different from that in the control group (20.0%), thus failing to validate the efficacy of FMT in UC. These two RCTs were the first to investigate FMT for UC, but the conflicting results raised concerns. This discrepancy may be attributed to the significant differences in the administration routes and frequencies of FMT. Although FMT has demonstrated high success rates in treating CDI, regardless of the administra- 69 Ishikawa D, et al: Applications of fecal microbiota transplantation Table 1 Double-blind RCT of FMT for UC Author, year Rossen et al. 201518) Moayyedi et al. 201519) Paramsothy et al. 201720) Costello et al. 201921) Haifer et al. 202122) Crothers et al. 202123) Patients No. 48 (FMT:23, placebo:25) 75 (FMT:38, placebo:37) 81 (FMT:41, placebo:40) 73 (FMT:38, placebo:35) 35(FMT:15, placebo:20) 12 (FMT:6, placebo:6) Pretreatment Bowel lavage none Bowel lavage Bowel lavage Amoxicillin, doxycycline, metronidazole. Ciprofloxacin, metronidazole & Bowel lavage FMT times 2 times 6 times 41 times 3 times 49 times 85 times Route of administration 500ml Duodenal 50ml enema infusions 150ml colonoscopy, enema 200ml colonoscopy, 100ml enema 6 lyophilized oral capsules 120ml colonoscopy, 550μl oral capsule Regimen of administration 2 nasoduodenal infusions 3 weeks apart Weekly enemas for 6 weeks Colonoscopic infusion followed by enemas 5 times/ week for 8 weeks Colonoscopic infusion followed by 2 enemas in 1week First week: 4 times a day. second week: Twice daily. Followed 6 weeks: once daily. Colonoscopic infusion followed by oral capsule daily for 12weeks Placebo autologous water processed isotonic autologous saline double encapsulated sham Donor single single multiple (3-7 donor) multiple (3-4 donor) single single Stool fresh fresh/ frozen frozen −80° C frozen −80° C lyophilised frozen −20° C Primary endpoint (FMT vs. placebo) CR+ER at week 12 30% vs. 20%, p=0.51 CR+ER/Er at CR+ER at week 7 week 8 24% vs. 5%, 27% vs. 8%, p=0.03 p=0.02 CR+ER/Er at CR+ER at week 8 week 8 32% vs. 9%, 53% vs. 15%, p=0.03 p=0.027 CR at week 12 2/6 vs. 0/6, p=0.45 FMT: fecal microbiota transplantation, CR: Clinical remission, ER: Colonoscopic remission, Er: Colonoscopic response, RCT: randomized controlled trial, UC: ulcerative colitis. tion method, these results indicate the need for a standardized FMT protocol for UC. Analysis of the gut microbiota revealed the recovery of diversity and similarity between the donor and recipient microbiota. Notably, Rossen et al.18) reported that remission was associated with butyrate-producing bacteria, specifically Clostridium clusters IV and XIVa. However, similar changes in the gut microbiota were also observed among responsive patients in the placebo group. This result suggests that these microbiota changes are part of the improvement, rather than the mechanisms of the therapeutic effect. Therefore, the precise mechanism of action FMT remains unclear. Paramsothy et al.20) reported the third RCT on FMT for UC in February 2017. This study increased the diversity of donor stools by mixing stool samples from three to seven donors. The patients underwent FMT via colonoscopy, followed by self-administered enemas five times per week for 8 weeks, totaling 41 FMT treatments. Despite the use of stringent evaluation criteria (requiring both clinical 70 and endoscopic remissions while gradually tapering corticosteroids), the FMT group achieved a 27% remission rate, which was significantly higher than the 8% remission rate in the isotonic saline control group. However, the complexity of this treatment method, which involves 40 self-administered enemas using frozen donor stool, raises concerns about its practicality as a treatment approach. In 2019, Costello et al.21) reported successful remission after only three FMT administrations using a solution prepared under anaerobic conditions. The latest RCT, conducted in 202122), used freeze-dried donor stool capsules for oral intake. After taking the three types of antibiotics for two weeks, the patients continued to take the capsules for eight weeks, achieving a 73% clinical remission rate, which was a remarkable result. In the same year, Crother et al.23) published a study involving 12 patients with UC. Despite performing 85 FMT procedures, only two of the six patients in the FMT group achieved remission by week 12, revealing no significant difference compared with the placebo group. Although Juntendo Medical Journal 71(2), 2025 the conclusions of the six RCTs were inconsistent, a network meta-analysis comparing FMT with five biologics currently used as standard therapy for severe refractory UC revealed that FMT is comparable to biologics in terms of remission and symptom improvement rates24). Only one RCT25) reported the use of FMT in the treatment of Crohn’s Disease (CD), but the findings were not promising, as no significant difference was observed in the remission rates between the FMT and control groups. This outcome may be related to the characteristics of CD lesions, which can extend into the small intestine, rendering their administration more difficult. Therefore, the location of the lesion, whether in the colon or the small intestine, may be a critical factor influencing remission, highlighting the need for further research to control variables such as lesion location. Our team’s application of FMT in UC The human gut microbiota26) consists of up to 3.8 ×1013 trillion bacteria, and FMT in isolation cannot ensure efficient colonization of donor bacteria, limiting its ability to effectively improve gut dysbiosis. To overcome this challenge, we administered three oral antibiotics ─ amoxicillin, fosfomycin, and MNZ (AFM) ─ for two weeks prior to FMT. This approach aimed to reduce the recipient’s original gut microbiota, thereby facilitating the efficient colonization of the transplanted bacteria. This combination therapy is referred to as “antibioticFMT” (A-FMT). The use of antibiotic-assisted FMT therapy has been documented in a previous study. Borody et al.27) reported a high cure rate using VCM, rifampicin, and MNZ as pre-treatments, followed by five sessions of FMT. To establish a more effective FMT protocol for the treatment of UC, we modified an antibiotic therapy (amoxicillin, tetracycline, and MNZ; ATM) that was previously reported to be effective for UC28) by replacing tetracycline with fosfomycin and proposed the A-FMT protocol. We treated 41 patients with UC29), of whom 21 received A-FMT and 20 received AFM alone. The results revealed that the proportion of Bacteroidetes significantly decreased after AFM therapy. By the 4th week after FMT, the Bacteroidetes levels had significantly recovered in patients who responded to treatment, while no recovery was observed in non-responders. By contrast, the AFM-alone group demonstrated insufficient recovery after 4 weeks, with no observed correlation to the treatment outcomes. These findings suggest a strong association between Bacteroidetes recovery and the efficacy of A-FMT. A subsequent species-level analysis of Bacteroidetes demonstrated that responders experienced improved species-level diversity after A-FMT, with their gut microbiota composition becoming more similar to that of the donor30). This outcome marked the first instance that antibiotic pre-treatment in AFM therapy facilitated the efficient colonization of donor gut microbiota, with successful colonization observed among responders. Donor matching and long-term responders Increasing evidence highlighted the critical role of compatibility between donor and recipient microbiomes in achieving a sustained response through cross-individual microbiota interactions31, 32). Donorpatient matching has emerged as a pivotal factor influencing the efficacy of A-FMT, paving the way for the development of stratified FMT approaches and microbiome-based drug discovery. In another study33), short-term therapeutic outcomes did not reveal a correlation between the donor-patient relationship and therapeutic success. However, a 2-year long-term follow-up revealed that sibling transplantation and a donor-patient age difference of less than 10 years were associated with longterm remission. Notably, in a case where the younger brother served as the donor, a single A-FMT treatment resulted in a 2-year sustained remission. A species-level gut microbiota analysis revealed efficient and stable transplantation of the donor’s gut microbiota, particularly the Bacteroidota species, into the sibling’s gut, with minimal changes over the 2 years. Knoll et al.34) have also reported that microbiota reshaping therapy using siblings as donors is a viable treatment option for children with UC. The sibling’s gut microbiota closely resemble that of the patient’s microbiota prior to disease onset, whereas dysbiosis creates a structural difference between the patient’s microbiota and that of their siblings. Transplanting a microbiota with a composition similar to that in the pre-disease state may facilitate the patients to return to their pre-disease condition and achieve more stable colonization. Therefore, we propose that these siblings could 71 Ishikawa D, et al: Applications of fecal microbiota transplantation serve as optimal donors for microbiota reshaping therapy for IBD. Expansion of FMT indications The indications for FMT are not limited to the treatment of rCDI and UC. The processing of fecal solutions used in FMT promotes the development of microbiome-based drugs (fecal-derived preparations), which can broaden its applications to treat a wider range of diseases. Application of FMT and immune checkpoint inhibitors In 2020, Science published a case study involving 10 patients with anti-programmed cell death 1 (PD-1) resistant metastatic melanoma, who were treated with FMT followed by re-administration of anti-PD-1 therapy. The results revealed partial efficacy in two patients and significant efficacy in one35). In the same year, Science published another clinical study36) evaluating the safety and efficacy of FMT combined with anti-PD-1 in patients with PD-1-refractory melanoma. A recent review37) indicated that 37.5% of patients with melanoma who were previously resistant to immune checkpoint inhibitors (ICI) immunotherapy exhibited complete or partial response after FMT and subsequent immunotherapy. No serious FMT-related adverse events were reported. These findings underscore the potential of FMT and suggest a significant association between gut bacteria and cancer immunity, paving the way for the development of microbiome-based therapeutics. Application of FMT and allergic diseases Exposure to the infant microbiome shortly after birth is crucial for the development of protective immunity and immune tolerance. Disruption of microbial exposure may increase vulnerability to infections in newborns or contribute to a higher risk of developing allergies and autoimmune diseases38). Similarly, changes in the gut microbiota of infants after birth have been associated with the development of allergies39). However, no consensus exists regarding which microbes play a protective role or are associated with an increased risk of developing allergies. Infants born via vaginal delivery are colonized by their mother’s gut microbiota40, 41), whereas those 72 born via cesarean section are less exposed to these bacteria41), leading to differences in the composition of their microbiomes42). A study that performed FMT using diluted maternal feces from newborns delivered via cesarean section found significant similarities to the gut microbiota of infants born through vaginal delivery43). This finding suggests that, unlike in adult patients, FMT can induce significant changes in the gut microbiota of infants, making it a potential strategy for preventing allergies. Therefore, A-FMT may be an effective treatment option for pediatric patients with allergic diseases. Application of FMT and central nervous system diseases In recent years, the increasing prevalence of autism spectrum disorder (ASD) worldwide has garnered significant attention44). The etiology of ASD remains unclear, and no effective treatment is available45). ASD, a neurodevelopmental disorder in children, is associated with gut microbiota dysbiosis46). In addition to abnormal neurological behaviors, children with ASD typically exhibit significant gastrointestinal symptoms47). The gut microbiota influences brain development and behavior through the gut-brain axis48). FMT has been reported to improve both behavioral and gastrointestinal symptoms in ASD by modulating the gut microbiota49). Furthermore, several studies50-52) have linked the gut microbiota to various neurological disorders. Animal experiments in mice have shown a potential link between gut microbiota composition changes and Alzheimer’s disease (AD)53). An 82-year-old male patient with AD demonstrated improvements in cognitive function, memory, and mood after receiving FMT from his 85-year-old wife54). Additionally, a 90-year-old female with AD and severe CDI underwent FMT from a 27-year-old healthy male donor, resulting in improved cognitive function, microbiota diversity, and Short-Chain Fatty Acids production55). Nevertheless, related studies remain limited. The therapeutic potential of FMT in multiple neurological disorders warrants further investigation. Application of FMT and metabolic disease The gut microbiota is one of the key regulatory systems for energy and substrate metabolism in the human body. Dysbiosis of the gut microbiota Juntendo Medical Journal 71(2), 2025 can lead to metabolic imbalances, contributing to chronic inflammation, insulin resistance, obesity, and other metabolic disorders. Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, affecting 537 million adults globally56). Modulating the composition of the gut microbiota in patients with T2DM may offer a novel therapeutic approach. In T2DM mice receiving FMT, HbA1c levels decreased, inflammatory factors such as Interleukin-6 (IL-6) and Tumor Necrosis Factor Alpha (TNF-α) were reduced, and both pancreatic islet function and insulin sensitivity improved57). In clinical trials, FMT-treated obese patients with T2DM acquired ≥20% lean-associated microbiota by week2458). Another study demonstrated that the gut microbiota of patients with T2DM was remodeled after FMT, leading to significant reductions in blood glucose and glycated hemoglobin levels59). By increasing beneficial bacterial species and altering the gut microbiota composition, FMT may play a regulatory role in metabolism for patients with T2DM. Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder characterized by the accumulation of fat in the liver60). The number of preclinical and clinical studies evaluating the efficacy of FMT in the treatment of NAFLD has been increasing. Additionally, the role of gut microbiota in patients with other liver diseases has also attracted attention.61). Nevertheless, the limited number of studies investigating the use of FMT in the treatment of liver diseases is insufficient to draw definitive conclusions. Future outlook of FMT Around the world, research is intensively focused on the impact of FMT on various disease areas. Therefore, it is highly likely that in the future, the best stool donors will be selected based on individual patient conditions and disease information, which is also what we hope to see. However, this tailored FMT requires determining the optimal conditions for matching donors with recipients, identifying and selecting specific microbes or microbial combinations with therapeutic potential, and establishing global donor screening standards to ensure safety and stability. Additionally, long-term efficacy and safety of personalized FMT treatment need to be tracked. If the key baceria or super-donors essential for treatment can be identified, it may become possible to simulate the microbial environment of superdonor feces and produce artificial feces. This could then be administered to patients, along with key microbial strains ─ similar to the widely recognized lactic acid bacteria ─ through enhanced oral supplementation. This approach would improve both the psychological and physical acceptance of FMT by patients while reducing the risk of exposure to infectious diseases. This is a path that requires rigorous and rapid development. Conclusion Research on FMT is actively being conducted worldwide. In the United States, FMT has progressed to the clinical application stage. In November 2022, the Ferring Pharmaceuticals’ microbiota-based enema solution, REBYOTA, received approval from regulatory authorities for the treatment of CDI. In Australia, BiomeBank’s FMT solution for CDI has also received regulatory approval. Our research team is committed to establishing an effective and safe foundation for FMT in Japan. As of March 2023, our institution has enrolled approximately 240 patients with UC and 240 donors participating in our study. We aim to clarify the therapeutic mechanisms and explore more effective treatment methods through multi-faceted analysis of the accumulated data. This research will also significantly contribute to the establishment of “fundamental gut microbiota therapy” for refractory diseases and other conditions associated with dysbiosis. Acknowledgments Not applicable. Funding The authors received no financial support for the research. Author contributions DI provided the initial draft concept, and XZ completed the writing of the detailed content. The manuscript was subsequently reviewed and approved by DI and AN All authors read and approved the final manuscript. 73 Ishikawa D, et al: Applications of fecal microbiota transplantation Conflicts of interest statement The authors declare that there are no conflicts of interest. Availability of data and materials Not applicable. References 1) Choi HH, Cho YS: Fecal microbiota transplantation: Current applications, effectiveness, and future perspectives. Clin Endosc, 2016; 49: 257-265. 2) Borody TJ, Paramsothy S, Agrawal G: Fecal microbiota transplantation: Indications, methods, evidence, and future directions. Curr Gastroenterol Rep, 2013; 15: 337. 3) van Nood E, Vrieze A, Nieuwdorp M, et al: Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med, 2013; 368: 407-415. 4) Cammarota G, Ianiro G, Tilg H, et al: European consensus conference on faecal microbiota transplantation in clinical practice. Gut, 2017; 66: 569-580. 5) McDonald LC, Gerding DN, Johnson S, et al: Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis, 2018; 66: e1-e48. 6) Quraishi MN, Widlak M, Bhala N, et al: Systematic review with meta-analysis: The efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther, 2017; 46: 479-493. 7) Lopetuso LR, Deleu S, Godny L, et al: The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease. Gut, 2023; 72: 1642-1650. 8) Cymbal M, Chatterjee A, Baggott B, Auron M: Management of Clostridioides difficile infection: Diagnosis, treatment, and future perspectives. Am J Med, 2024; 137: 571-576. 9) Guery B, Galperine T, Barbut F: Clostridioides difficile: diagnosis and treatments. BMJ, 2019; 366: l4609. 10) Riley TV, Kimura T: The epidemiology of Clostridium difficile infection in Japan: a systematic review. Infect Dis Ther, 2018; 7: 39-70. 11) Eiseman B, Silen W, Bascom GS, Kauvar AJ: Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery, 1958; 44: 854-859. 12) McDonald LC, Gerding DN, Johnson S, et al: Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis, 2018; 66: 987-994. 13) Czepiel J, Dróżdż M, Pituch H, et al: Clostridium difficile infection: Review. Eur J Clin Microbiol Infect Dis, 2019; 38: 1211-1221. 14) Okabayashi S, Kobayashi T, Hibi T: Inflammatory bowel disease in Japan ─ Is it similar to or different from Westerns? J Anus Rectum Colon, 2020; 4: 1-13. 15) Stallmach A, Hagel S, Bruns T: Adverse effects of 74 biologics used for treating IBD. Best Pract Res Clin Gastroenterol, 2010; 24: 167-182. 16) Zenlea T, Peppercorn MA: Immunosuppressive therapies for inflammatory bowel disease. World J Gastroenterol, 2014; 20: 3146-3152. 17) Bennet JD, Brinkman M: Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet, 1989; 1: 164. 18) Rossen NG, Fuentes S, van der Spek MJ, et al: Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology, 2015; 149: 110-118. e4. 19) Moayyedi P, Surette MG, Kim PT, et al: Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology, 2015; 149: 102-109. e6. 20) Paramsothy S, Kamm MA, Kaakoush NO, et al: Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet, 2017; 389: 1218-1228. 21) Costello SP, Hughes PA, Waters O, et al: Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA, 2019; 321: 156-164. 22) Haifer C, Paramsothy S, Kaakoush NO et al: Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol, 2022; 7: 141-151. 23) Crothers JW, Chu ND, Nguyen LTT, et al: Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study. BMC Gastroenterol, 2021; 21: 281. 24) Zhou HY, Guo B, Lufumpa E, et al: Comparative of the effectiveness and safety of biological agents, tofacitinib, and fecal microbiota transplantation in ulcerative colitis: systematic review and network meta-analysis. Immunol Invest, 2021; 50: 323-337. 25) Sokol H, Landman C, Seksik P, et al: Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study. Microbiome, 2020; 8: 12. 26) Sender R, Fuchs S, Milo R: Revised estimates for the number of human and bacteria cells in the body. PLoS Biol, 2016; 14: e1002533. 27) Borody TJ, Warren EF, Leis S, Surace R, Ashman O: Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol, 2003; 37: 42-47. 28) Ohkusa T, Kato K, Terao S, et al: Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol, 2010; 105: 1820-1829. 29) Ishikawa D, Sasaki T, Osada T, et al: Changes in intestinal microbiota following combination therapy with fecal microbial transplantation and antibiotics for ulcerative colitis. Inflamm Bowel Dis, 2017; 23: 116-125. 30) Ishikawa D, Sasaki T, Takahashi M, et al: The microbial composition of Bacteroidetes species in ulcerative colitis is effectively improved by combination therapy with fecal microbiota transplantation and antibiotics. Inflamm Bowel Dis, 2018; 24: 2590-2598. 31) Kazemian N, Ramezankhani M, Sehgal A, et al: Author correction: The trans-kingdom battle between donor and recipient gut microbiome influences fecal microbiota transplantation outcome. Sci Rep, 2021; 11: 4546. Juntendo Medical Journal 71(2), 2025 32) Li SS, Zhu A, Benes V, et al: Durable coexistence of donor and recipient strains after fecal microbiota transplantation. Science, 2016; 352: 586-589. 33) Okahara K, Ishikawa D, Nomura K, et al: Matching between donors and ulcerative colitis patients is important for long-term maintenance after fecal microbiota transplantation. J Clin Med, 2020; 9: 1650. 34) Knoll RL, Forslund K, Roat Kultima J, et al: Gut microbiota differs between children with inflammatory bowel disease and healthy siblings in taxonomic and functional composition: a metagenomic analysis. Am J Physiol Gastrointest Liver Physiol, 2017; 312: G327-G339. 35) Baruch EN, Youngster I, Ben-Betzalel G, et al: Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science, 2021; 371: 602-609. 36) Davar D, Dzutsev AK, McCulloch JA, et al: Fecal microbiota transplant overcomes resistance to antiPD-1 therapy in melanoma patients. Science, 2021; 371: 595-602. 37) Natarelli N, Aflatooni S, Boby A, Krenitsky A, Grichnik J: The gastrointestinal microbiome and immune checkpoint inhibitors: a review of human interventional studies among melanoma patients. J Drugs Dermatol, 2024; 23: 78-84. 38) Reynolds HM, Bettini ML: Early-life microbiota-immune homeostasis. Front Immunol, 2023; 14: 1266876. 39) Penders J, Stobberingh EE, van den Brandt PA, Thijs C: The role of the intestinal microbiota in the development of atopic disorders. Allergy, 2007; 62: 1223-1236. 40) Dominguez-Bello MG, Costello EK, Contreras M, et al: Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A, 2010; 107: 1197111975. 41) Backhed F, Roswall J, Peng Y, et al: Dynamics and stabilization of the human gut microbiome during the first year of Life. Cell Host Microbe, 2015; 17: 690-703. 42) Houghton LA, et al: The role of diet and the microbiome in inflammation and autoimmunity. J Nutr Biochem, 2019; 70: 73-86. 43) Korpela K, Helve O, Kolho K-L, et al: Maternal fecal microbiota transplantation in cesarean-born infants rapidly restores normal gut microbial development: a proof-of-concept study. Cell, 2020; 183: 324-334 e5. 44) Zeidan J, Fombonne E, Scorah J, et al: Global prevalence of autism: a systematic review update. Autism Res, 2022; 15: 778-790. 45) Svoboda E: Could the gut microbiome be linked to autism? Nature, 2020; 577: S14-S15. 46) Sanlier N, Kocabas S: The effect of probiotic, prebiotic and gut microbiota on ASD: a review and future perspec- tives. Crit Rev Food Sci Nutr, 2023; 63: 2319-2330. 47) Leader G, Abberton C, Cunningham S, et al: Gastrointestinal symptoms in autism spectrum disorder: a systematic review. Nutrients, 2022; 14: 1471. 48) Saurman V, Margolis KG, Luna RA: Autism spectrum disorder as a brain-gut-microbiome axis disorder. Dig Dis Sci, 2020; 65: 818-828. 49) Kang DW, Adams JB, Coleman DM, et al: Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota. Sci Rep, 2019; 9: 5821. 50) Chen CC, Chiu CH: Current and future applications of fecal microbiota transplantation for children. Biomed J, 2022; 45: 11-18. 51) Liptak R, Gromova B, Gardlik R: Fecal microbiota transplantation as a tool for therapeutic modulation of non-gastrointestinal disorders. Front Med (Lausanne), 2021; 8: 665520. 52) Borsom EM, Lee K, Cope EK: Do the bugs in your gut eat your memories? Relationship between gut microbiota and Alzheimer’s disease. Brain Sci, 2020; 10: 814. 53) Chok KC, Ng KY, Koh RY, et al: Role of the gut microbiome in Alzheimer’s disease. Rev Neurosci, 2021; 32: 767-789. 54) Hazan S: Rapid improvement in Alzheimer’s disease symptoms following fecal microbiota transplantation: A case report. J Int Med Res, 2020; 48. 55) Park SH, Lee JH, Shin J, et al: Cognitive function improvement after fecal microbiota transplantation in Alzheimer’s dementia patient: A case report. Curr Med Res Opin, 2021; 37: 1739-1744. 56) Xiaolan Z, Rumeng C, Yichen C, et al: Fecal Microbiota Transplantation: A Prospective Treatment for Type 2 Diabetes Mellitus. Diabetes Metab Syndr Obes, 2024; 17: 647-659. 57) Wang H, Lu Y, Yan Y, et al: Promising treatment for type 2 diabetes: fecal microbiota transplantation reverses insulin resistance and impaired islets. Front Cell Infect Microbiol, 2019; 9: 455. 58) Ng SC, Xu Z, Mak JWY, et al: Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial. Gut, 2022; 71: 716-723. 59) Ding D, Yong H, You N, et al: Prospective study reveals host microbial determinants of clinical response to fecal microbiota transplant therapy in type 2 diabetes patients. Front Cell Infect Microbiol, 2022; 12: 820367. 60) Qiu XX, Cheng SL, Liu YH, et al: Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect. World J Gastroenterol, 2024; 30: 833-842. 61) Yang Y, Schnabl B: Gut Bacteria in Alcohol-Associated Liver Disease. Clin Liver Dis, 2024; 28: 663-679. 75